Appendix Table 23KQ4 Withdrawals due to adverse events—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Study, YearDesignPopulationOutcome/DefinitionGroupEvents, n/NEvents, “X”R (95% CI)
HOPE, 200038RCTCAD, Stroke, PVD or DM + 1 Risk FactorNRRamipril 10mg/dNRNR
PART-2, 200041RCTMI, angina with confirmed CAD, TIA or ICSuspected adverse drug reactions leading to stopping randomized treatmentRamipril 5–10mg/d
Placebo
31/308
3/309
NR
SCAT, 200042RCTCoronary atherosclerosis in >3 major arteries, elevated cholesterolNREnalapril 20mg/d
Placebo
NRNR
EUROPA, 200343RCTCAD (previous MI, revasc. or>70% coronary artery narrowing) without HFNRPerindopril 8mg/d
Placebo
NRNR
Kondo et al, 200344RCTH/o coronary intervention with no significant stenosis on 6 mo f/o angiographyNRCandesartan 4mg/d
Control
NRNR
CAMELOT, 200445RCTPCI or chest pain requiring coronary angiographyDiscontinuations due to adverse eventsEnalapril 20mg/d
Amlodipine 10mg/d
Placebo
102/673
87/663
71/655
NR
JMIC-B, 200446RCTHypertension and CADWithdrawals due to adverse eventsACEI[proportional, variant]
Nifedipine 10–20mg/d
72/822
41/828
NR
PEACE, 200447RCTDocumented CADSide effects leading to discontinuation of study medicationTrandolapril 4mg/d
Placebo
599/4158
269/4132
NR
FOSIDIAL, 200648RCTHemodialysis and LVHNRFosinopril 20mg/d
Placebo
NRNR
Takahashi et al, 200649RCTChronic maintenance hemodialysisNRCandesartan 4–8mg/d
Control
NRNR
SMILE-ISCHEMIA, 200750RCTMI within 6 weeksNRZofenopril 60mg/d
Placebo
NRNR
TRANSCEND, 200851RCTCAD, Cerebrovascular disease, PVD, or DM + end-organ damageNRTelmisartan 80mg/d
Placebo
NRNR
[proportional, variant]

= Patients in the ACEI group were given enalapril 5–10mg/d, imidapril 5–10mg/d, or lisinopril 10–20mg/d;

= Patients in the ACEI group were given enalapril 5–10mg/d, imidapril 5–10mg/d, or lisinopril 10–20mg/d;

From: Appendix C, Additional Evidence Tables and Analyses

Cover of Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease [Internet].
Comparative Effectiveness Reviews, No. 18.
Coleman CI, Baker WL, Kluger J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.